APA (7th ed.) Citation

Peng, H., Chai, Y., Gong, C., Hao, Y., Peng, Y., Zhang, W., . . . Wang, Q. (2026). PEGylated thymosin β4 is a thiol‐site‐specific prodrug treating myocardial infarction in vivo. Bioengineering & Translational Medicine, 11(4), 1. https://doi.org/10.1002/btm2.70144

Chicago Style (17th ed.) Citation

Peng, Haisheng, et al. "PEGylated Thymosin β4 Is a Thiol‐site‐specific Prodrug Treating Myocardial Infarction in Vivo." Bioengineering & Translational Medicine 11, no. 4 (2026): 1. https://doi.org/10.1002/btm2.70144.

MLA (9th ed.) Citation

Peng, Haisheng, et al. "PEGylated Thymosin β4 Is a Thiol‐site‐specific Prodrug Treating Myocardial Infarction in Vivo." Bioengineering & Translational Medicine, vol. 11, no. 4, 2026, p. 1, https://doi.org/10.1002/btm2.70144.